Quick Takeaways
- CITADEL ADVISORS LLC filed SCHEDULE 13G/A for VYNE Therapeutics Inc. Common Stock, par value $0.0001 (VYNE).
- Disclosed ownership: 7.2%.
- Date of event: 31 Mar 2025.
Quoteable Key Fact
"CITADEL ADVISORS LLC disclosed 7.2% ownership in VYNE Therapeutics Inc. Common Stock, par value $0.0001 (VYNE) on 31 Mar 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 6.8% | 1,040,070 | 0 | 1,040,070 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Advisors Holdings LP | 6.8% | 1,040,070 | 0 | 1,040,070 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel GP LLC | 6.8% | 1,040,070 | 0 | 1,040,070 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities LLC | 0.4% | 58,260 | 0 | 58,260 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Citadel Securities Group LP | 0.4% | 60,259 | 0 | 60,259 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Citadel Securities GP LLC | 0.4% | 60,259 | 0 | 60,259 | /s/ Guy Miller | Guy Miller, Authorized Signatory | |
| Kenneth Griffin | 7.2% | 1,100,329 | 0 | 1,100,329 | /s/ Seth Levy | Seth Levy, attorney-in-fact* |